01Identity
What is it?
The starting material may be a single authorised preparation or a multi-ingredient formulation; every active and inactive component must be declared.
Aesthetic Mesotherapy · Aesthetic Medicine · Istanbul
Aesthetic Mesotherapy · Aesthetic Medicine · Istanbul
Aesthetic Mesotherapy
Mesotherapy describes a delivery approach, not one medicine or a standard cocktail. Hyaluronic acid, vitamins, amino acids, peptides, medicines or other ingredients may be marketed under the same term even though their manufacture, authorisation and evidence differ.
A named formulation and a clear clinical target must replace the idea of a personalised secret mixture. This page does not provide a mixing, dilution or injection protocol.
Quick Orientation
Identity · composition · preparation · route
The treatment name is only the start of the medical description.
A responsible discussion identifies the exact preparation or device, how it was made, where it is intended to act and which clinical question is being assessed.
02Production
How is it prepared?
Manufacturer, sterile production, container, batch, shelf life, storage and any preparation before use form one traceable product chain.
03Route
How does it reach tissue?
Small local injections may expose dermal or subdermal tissue; the precise route and intended tissue must match the product information and clinical rationale.
04Target
What is the clinical target?
A limited skin-quality or symptom question is defined before treatment and kept separate from hair mesotherapy, fillers and fat-directed injections.
What is Aesthetic Mesotherapy?
A delivery label, not a single product
Formulation and route define what aesthetic mesotherapy actually means.
The intended role, product identity and target tissue stay visible so unlike procedures are not presented as one interchangeable class.
What Aesthetic Mesotherapy can do
- Evaluate one identifiable formulation for one defined skin question
- Keep manufacturer, batch, composition and route traceable
- Separate local tolerability from a later clinical endpoint
- Stop when product identity, status or evidence is inadequate
What Aesthetic Mesotherapy cannot do
- Treat mesotherapy as one standard product or cocktail
- Assume an ingredient safe on skin is safe by injection
- Transfer findings between unlike formulas or routes
- Promise rejuvenation, hydration, collagen production or permanence
An undeclared mixture, unclear manufacturer, uncertain sterile pathway or unsupported injection use is a reason not to proceed.
Medical Suitability
Clinical question before method selection
Five checks precede any personal decision.
Skin findings, allergies, medicines, previous reactions and the exact formulation are considered together. A request for glow or rejuvenation is not a diagnosis.
- 01
Define the clinical question
Dryness, texture, pigmentation, inflammation and volume concerns require different assessment and may need another form of care.
- 02
Examine the skin
Barrier damage, infection, active dermatitis, acne, scarring tendency and pigment risk may alter or exclude treatment.
- 03
Audit the formula
Every ingredient, concentration, excipient, manufacturer, batch, storage condition and intended route is checked.
- 04
Review personal factors
Allergy history, pregnancy or breastfeeding, immune status, medicines and healing history may change suitability.
- 05
Compare alternatives
Topical care, observation, a product with clearer evidence or a non-injectable option may be more proportionate.
Product and Treatment Path
Traceability without a public injection recipe
Every vial and every preparation step must remain identifiable.
Combining products changes the final exposure. Compatibility, sterility and intended use cannot be assumed because ingredients are individually familiar.
01Source
Formula and manufacturer
The complete product information is reviewed before any clinical discussion.
- Record active and inactive ingredients
- Verify manufacturer, batch and expiry
- Check authorisation for route and indication
02Preparation
Sterility and compatibility
Any reconstitution or combination must have a documented basis; informal mixing is not presented as personalisation.
- Follow product-specific handling
- Do not infer mixture compatibility
- Retain storage and preparation records
03Use
Route and target tissue
The intended tissue, treated region and review endpoint are stated without publishing an injection map.
- Name the route and tissue
- Record region and product used
- Define early and later review points
This page does not recommend a formula, dose, dilution, injection depth, point pattern, needle, cannula or session programme.
Evidence and Limits
Read the data at product and indication level
Evidence belongs to the studied formulation, not to mesotherapy as a whole.
Human studies use different ingredients, comparators, techniques and short-term scales. A result from one small study cannot validate every cocktail or route.
Identify the exact formula
A study supports only the preparation and handling that were actually investigated.
Read the endpoint
Short-term appearance ratings do not establish structural change, prevention or lasting benefit.
Check study design
Small, uncontrolled or non-blinded studies leave important uncertainty about effect size and bias.
Keep safety product-specific
Adverse-event data for one ingredient cannot clear an undeclared multi-ingredient mixture.
The available literature does not justify a universal mesotherapy recipe, a fixed course or a personal response prediction.
Individual Plan
One indication · one traceable intervention · one review point
A defensible plan starts with one declared product and one endpoint.
The clinical question, exact formulation, route, uncertainty and stop criteria are documented before any decision to treat.
Set the baseline
Record the skin finding, previous care, photographs and the outcome that would count as meaningful.
Verify the product
Composition, manufacturer, batch, storage, route and country-specific status stay visible.
Limit the first decision
No package is justified before tolerability and the defined clinical target can be reviewed.
Predefine stopping
Unclear benefit, persistent inflammation, nodules or an unexpected reaction end automatic repetition.
Course and Follow-Up
Expected reaction · adverse effect · clinical endpoint
Injection reactions and a later skin endpoint require separate timelines.
Redness, swelling, bruising or tenderness may reflect the procedure and must not be presented as evidence that the formulation is working.
- 01Treatment day
Record exposure
Product, batch, route, region and immediate reaction are documented.
- 02Early review
Check early safety
Increasing pain, spreading redness, discharge, fever, colour change or unusual swelling needs in-person review.
- 03Clinical review
Compare the endpoint
Only the pre-defined skin feature is reviewed under comparable conditions.
- 04Decision
Apply the stop rule
No objective signal or unresolved adverse effect does not support automatic repetition.
Risks and Alternatives
Material, anatomy and route shape risk
More ingredients create more questions, not automatic added benefit.
Injection-related injury sits alongside allergy, infection, inflammation and uncertainty about the final mixture.
01Procedure
Local and infectious
Pain, bruising, swelling, bleeding, persistent redness, infection and pigment change may occur.
02Formula
Product and immune
Allergy, hypersensitivity, inflammatory nodules or reactions to an active ingredient or excipient are possible.
03Anatomy
Anatomical injury
Vascular compromise, tissue injury and unintended deeper exposure are uncommon but clinically important.
04Urgency
Take warning signs seriously
Increasing pain, unusual discolouration, rapid swelling, fever or painful nodules need early assessment.
Increasing pain, blanching or mottled colour, visual change, rapidly enlarging swelling or systemic illness requires immediate local medical assessment. Alternatives may include simplified skin care, diagnosis-led topical treatment, observation or another evidence-matched procedure.
Istanbul and Follow-Up
A treatment decision must remain reviewable after travel
Assessment, product records and a local safety route travel together.
International care is not reduced to a treatment day. The in-person examination, exact intervention, early review and later endpoint are connected before departure.
01
Organise the question
History, previous procedures and the specific aesthetic mesotherapy question prepare the visit without confirming suitability.
02
Examine in person
Anatomy, tissue, active disease, product or device status, risks and alternatives are reviewed together.
03
Keep exact records
Product or device identity, batch where relevant, treated region, route and observations remain traceable.
04
Arrange review
Expected reactions, stop criteria, local medical access and the later clinical endpoint are agreed before return travel.
The Doctor Aslan Approach
Product-specific, anatomy-led and reversible in decision-making
Transparency replaces the idea of a proprietary cocktail.
Aesthetic mesotherapy is discussed only after the formula, manufacturer, route, target and evidence boundary are clear. A decision not to inject is a valid outcome.
Name the product
Generic labels are replaced by complete composition and traceability.
Separate the route
Topical, intradermal and subdermal exposures are not treated as equivalent.
Use a measured target
A defined skin question replaces general rejuvenation language.
Keep an exit route
Adverse effects, uncertainty or no meaningful signal stop automatic continuation.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about aesthetic mesotherapy; no personal protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is injected in aesthetic mesotherapy?+
Mesotherapy does not describe a fixed formula. Preparations, full composition, concentration and intended use may differ substantially. Before treatment, product name, active and inactive ingredients, batch, expiry, target area, injection layer and total quantity must be established; an unclear ‘cocktail’ is not adequate medical product information.
02Is aesthetic mesotherapy the same as skin boosters or hair mesotherapy?+
No. Aesthetic mesotherapy describes local microinjections for a limited skin concern. Skin boosters are classified separately by product and skin-quality aim; hair mesotherapy belongs to scalp and hair-loss treatment. Injection lipolysis also has a different task in subcutaneous fat. Similar punctures do not make these procedures interchangeable.
03How robust is the evidence for aesthetic mesotherapy?+
The data are not a uniform proof of effectiveness for the umbrella term mesotherapy. Studies examine particular formulations, small or differently composed groups, varied injection techniques and different endpoints; results for one preparation cannot be transferred to other mixtures. A general guarantee of rejuvenation, collagen production or hydration is not justified.
04Which symptoms after mesotherapy need prompt medical help?+
Increasing or severe pain, unusual pallor or net-like discolouration, rapidly growing swelling, visual change, fever, pus, spreading redness or painful persistent nodules require early local medical assessment. These symptoms must not wait for a later online response.
Next Step
Identify the formulation · define the skin question